This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology
Journal of Hematology & Oncology Open Access 02 March 2018
-
How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?
Journal of Hematology & Oncology Open Access 12 April 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparables outcomes with HLA-identical sibling transplantation. Blood 2006; 107: 3065–3073.
Mo XD, Xu LP, Liu DH, Zhang XH, Chen H, Chen YH et al. The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) is an outcome predictor for partially matched related donor transplantation. Am J Hematol 2013; 88: 497–502.
Wang HT, Chang YJ, Xu LP, Liu DH, Wang Y, Liu KY et al. EBMT risk score can predict the outcome of leukaemia after unmanipulated haploidentical blood and marrow transplantation. Bone Marrow Transplant 2014; 49: 927–933.
McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101: 2043–2048.
Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003; 102: 820–826.
de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857–864.
Wang FR, Huang XJ, Liu DH, Chen H, Wang Y, Tang FF et al. [The efficacy and safety of modified busulfan/fludarabine conditioning regimen in elderly or drug-intolerable patients with hematologic malignancies]. Zhonghua nei ke za zhi 2013; 52: 1028–1032.
Chen H, Lu DP, Huang XJ, Liu KY, Xu LP, Han W et al. [Reduced intensity of BuCy conditioning regimen for transplantation in the treatment of malignant hematologic diseases]. Zhonghua xue ye xue za zhi=Zhonghua xueyexue zazhi 2005; 26: 273–276.
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.
Lee JH, Joo YD, Kim H, Ryoo HM, Kim MK, Lee GW et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol 2013; 31: 701–709.
Lee JH, Joo YD, Kim H, Ryoo HM, Kim MK, Lee GW et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol 2013; 31: 701–709.
Liu DH, Xu LP, Zhang XH, Wang Y, Yan CH, Wang JZ et al. Substitution of cyclophosphamide in the modified BuCy regimen with fludarabine is associated with increased incidence of severe pneumonia: a prospective, randomized study. Int J Hematol 2013; 98: 708–715.
Liu H, Zhai X, Song Z, Sun J, Xiao Y, Nie D et al. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. J Hematol Oncol 2013; 6: 15.
Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468–476.
Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biology Blood Marrow Transplant 2008; 14: 672–684.
Acknowledgements
This work was supported in part by grants from National Natural Science Foundation of China (Grant No. 30971292), National Clinical Priority Specialty of Ministry of Health of China and National Science and Technology Pillar Program (Grant no. 2008BAI61B01) and Collaborative Innovation Center of Hematology. We thank the editage (www.editage.com) for editing and language revision of this paper.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Author contributions
X-jH designed the research and revised the paper. Y-qS, L-pX, X-hZ, D-hL, YW, C-hY, F-rW, J-zW, YJ, Y-yZ and K-yL performed the research. Y-qS analysed the data and wrote the paper.
Supplementary Information accompanies this paper on Bone Marrow Transplantation website
Supplementary information
Rights and permissions
About this article
Cite this article
Sun, Yq., Xu, Lp., Zhang, Xh. et al. A retrospective comparison of BU-fludarabine and BU–CY regimens in elderly patients or in patients with comorbidities who received unmanipulated haploidentical hematopoietic SCT. Bone Marrow Transplant 50, 601–603 (2015). https://doi.org/10.1038/bmt.2014.303
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2014.303
This article is cited by
-
Comparison of haploidentical hematopoietic stem cell transplantation with chemotherapy in older adults with acute myeloid leukemia
Bone Marrow Transplantation (2023)
-
Update of the “Beijing Protocol” haplo-identical hematopoietic stem cell transplantation
Bone Marrow Transplantation (2019)
-
Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation
Bone Marrow Transplantation (2019)
-
Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation
Frontiers of Medicine (2019)
-
The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology
Journal of Hematology & Oncology (2018)